跳至主要内容
临床试验/NCT00265369
NCT00265369已完成3 期

Comparative Efficacy and Safety of a Bacillus Clausii Probiotic Strain Versus Placebo in the Treatment of Acute Diarrhoea in Children

Sanofi2 个研究点 分布在 2 个国家目标入组 420 人开始时间: 2004年5月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Sanofi
入组人数
420
试验地点
2
主要终点
Duration of diarrhoea as counted from the first intake of the investigational product up to the first appearance of a loose stool followed by two-consecutive normal stools

研究概览

简要总结

Primary objective:

  • To demonstrate the efficacy of a Bacillus clausii probiotic strain compared to placebo in children suffering from acute diarrhoea and treated for 7 days.

Secondary objective:

  • To evaluate the clinical safety of the Bacillus clausii probiotic strain versus placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
6 Months 至 36 Months(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Infants or Children
  • •Non hospitalized infants or children
  • •With acute diarrhea evident for less than 48 hours
  • •Having had three or more watery stools during the preceding 24 hours

排除标准

  • •Infants or Children
  • •With blood stools
  • •Having been treated with antibiotics or probiotics within the two weeks before the enrollment
  • •Suffering from dehydration defined by a weight loss of at least 5% or by the presence of a skin fold
  • •With an history of seizures
  • •With immunosuppressive conditions
  • •With a current status requiring an antibiotic treatment
  • •Suffering from a chronic disease including chronic diarrhea whatever the origin
  • •Having received before inclusion one of the following treatments:
  • •Probiotics
  • •Prebiotics
  • •Drugs with adsorbing properties
  • •Drugs that modify intestinal secretion like bismuth subsalicylate, acetorphan
  • •Drugs that modify intestinal motility (opiates such as loperamide, atropine and other cholinergic agents).
  • •Having participated in another clinical trial in the last 3 months prior to the start of the study

结局指标

主要结局

Duration of diarrhoea as counted from the first intake of the investigational product up to the first appearance of a loose stool followed by two-consecutive normal stools

次要结局

  • Number of infants/children with normal stools at D3, D4, D5, D6 and D7;Mean number of stools per day;Occurrence of vomiting episodes per day after enrolment;Parents'overall global assessment of efficacy at the end of the treatment;other safety criteria

研究者

发起方
Sanofi
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验